

# **INDEX RULE BOOK**

## **Next Biotech Index**

Version 21-01

Effective from 15 Dec 2021

[indices.euronext.com](https://indices.euronext.com)

This publication is for information purposes only and is not a recommendation to engage in investment activities. This publication is provided "as is" without representation or warranty of any kind. Whilst all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. All proprietary rights and interest in or connected with this publication shall vest in Euronext. No part of it may be redistributed or reproduced in any form without the prior written permission of Euronext.

Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at <https://www.euronext.com/terms-use> .

© 2021, Euronext N.V. - All rights reserved.

For further information in relation to Euronext Indices please contact:  
[index-team@euronext.com](mailto:index-team@euronext.com)

# Index

<b>1. General</b>	<b>2</b>
Version notes	2
<b>2. Index reviews</b>	<b>3</b>
2.1 Review frequency and relevant dates	3
2.2 Review Selection	3
2.3 Periodical Weighting Update	3
<b>3. References</b>	<b>5</b>
3.1 Reference Table	5
3.2 Base currency	5
3.3 Publication	5
<b>4. ESG Disclosures</b>	<b>6</b>

## 1. GENERAL

---

This document is applicable to the Next Biotech Index ("Index Family"), which consists of all the Indices as mentioned in the Reference Table.

The Next Biotech Index is designed to reflect the price level trends in the trading of shares listed in Euronext markets.

Euronext Paris is the Administrator of this Index Family. For this Index Family no Independent Supervisor is appointed.

Euronext N.V. or its subsidiaries (hereinafter jointly "Euronext") owns all intellectual and other property rights to the index, including the name, the composition and the calculation of the index. Information regarding trademarks and intellectual property rights of Euronext is located at <https://www.euronext.com/terms-use>.

### VERSION NOTES

Version	Effective date	New or changed parts	Reference/announcement
21-01	15-12-2021	restyled version in view of newly published Calculation and Corporate Actions rulebooks	

## 2. INDEX REVIEWS

---

### 2.1 REVIEW FREQUENCY AND RELEVANT DATES

<b>Review frequency:</b>	Daily
<b>Review Effective Date:</b>	The inclusion of companies in the index will take place two weeks after the announcement of their changing of sector classification. IPOs are included two weeks after their first trading day.
<b>Review Cut-Off Date:</b>	Not applicable
<b>Review Announcement Date:</b>	The inclusion or removal of companies and other changes will be announced on a daily basis on the day before the changes are effective.
<b>Review Weighting Announcement Date:</b>	Not applicable

### 2.2 REVIEW SELECTION

#### Step 1: Index Universe

##### Index Universe definition

The Index Universe consists of companies listed on Euronext and Euronext Growth markets, classified (according to the ICB classification) as 20103010, Biotechnology.

##### Step 2: Eligibility screening at reviews

Not applicable

##### Step 3: Selection Ranking

Not applicable

##### Step 4: Selection of constituents at the reviews

Not applicable

### 2.3 PERIODICAL WEIGHTING UPDATE

#### Weighting method

The index is Full Market Capitalisation weighted.

The Weighting Factors are explained in the following paragraphs.

**Number of shares**

The Number Of Shares are updated daily based on the listed number of shares.

**Free Float factor**

The Free Float Factor is not applicable for the weightings of this Index Family.

**Capping Factor**

The Capping Factor is not applicable for the weightings of this Index Family.

### 3. REFERENCES

---

#### 3.1 REFERENCE TABLE

Index name	Isincode	Mnemo	Bloom- berg Code	Reuters code	Base date	Base value	Publication since	Index Type
Next Biotech	QS0011095955	BIOTK	BIOTK	.BIOTK	30-12- 05	1000	07-04-08	Price

#### 3.2 BASE CURRENCY

The Base Currency of this index family is Euro.

#### 3.3 PUBLICATION

The index is calculated daily and published at the close on the days when the Euronext Markets are open for trading.

## 4. ESG DISCLOSURES

EXPLANATION OF HOW ESG FACTORS ARE REFLECTED IN THE KEY ELEMENTS OF THE BENCHMARK METHODOLOGY	
<b>Item 1.</b> Name of the benchmark administrator.	Euronext Paris
<b>Item 2.</b> Type of benchmark	Equity Benchmark
<b>Item 3.</b> Name of the benchmark or family of benchmarks.	<b>Next Biotech index</b>
<b>Item 4.</b> Does the benchmark methodology for the benchmark or family of benchmarks take into account ESG factors?	No
<b>Item 5.</b> If the response to Item 4 is positive, please find below the ESG factors that are taken into account in the benchmark methodology and how they are used for selection, weighting and exclusion	
a) List of environmental factors considered:	Not applicable
b) List of social factors considered:	Not applicable
c) List of governance factors considered:	Not applicable
<b>Item 6.</b> Data and standards used.	
a) Data input. <i>(i) Describe whether the data are reported, modelled or, sourced internally or externally.</i> <i>(ii) Where the data are reported, modelled or sourced externally, please name the third party data provider.</i>	Not applicable
b) Verification of data and guaranteeing the quality of those data. <i>Describe how data are verified and how the quality of those data is ensured.</i>	Not applicable
c) Reference standards <i>Describe the international standards used in the benchmark methodology.</i>	Not applicable
<b>Information updated on:</b>	April 2021